XRAY & Siemens Healthineers Secure FDA Nod for Dental-Dedicated MRI
Dentsply Sirona XRAY and Siemens Healthineers have announced a breakthrough in dental imaging with the first dental-dedicated magnetic resonance imaging (ddMRI) system, the MAGNETOM Free.Max Dental Edition. The system has received clearance from the FDA in the United States, following a clinical trial that confirmed its strong potential and highlighted features tailored specifically for use across multiple dental specialties.
The MAGNETOM Free.Max Dental Edition can distinguish active inflammation from healthy or scar tissue, assess tooth pulp vitality non-invasively to support chairside evaluation and visualize teeth along with their spatial relationship to adjacent teeth and nearby nerves.
Management stated that the innovation strengthens the company’s imaging portfolio, which includes systems like Axeos, Orthophos SL and Heliodent Plus. The company is proud to help introduce the industry’s first dental-dedicated MRI and advance diagnostic capabilities in dentistry.
Andreas Schneck, head of magnetic resonance at Siemens Healthineers, emphasized its focus on expanding the clinical impact and accessibility of MRI technology. Successful clinical validation of dental-dedicated MRI highlights its potential to establish a new clinical area that could benefit both dental professionals and patients.
Likely Trend of XRAYXRAY-- Stock Following the News
Shares of XRAY have lost 7.8% since the announcement on Monday. Over the past six months, XRAY’s shares have dropped 12.9% against the industry’s 16.6% growth and the S&P 500’s 3.3% rise.
In the long run, the FDA clearance and clinical validation of a dental-dedicated MRI system would strengthen Dentsply Sirona’s competitive position in advanced dental imaging. By introducing a new diagnostic modality capable of capturing detailed soft-tissue information, the company broadens its imaging portfolio while reinforcing partnerships with major healthcare technology providers. This innovation may drive adoption among hospitals, large dental clinics and academic institutions, supporting long-term equipment sales, service revenues and technological leadership in dental diagnostics.
XRAY currently has a market capitalization of $2.54 billion.
Image Source: Zacks Investment Research
More on the ddMRI Innovation
The ddMRI is designed to support dentomaxillofacial diagnostics and complement existing imaging solutions such as intraoral, panoramic and cone-beam computed tomography scans. Unlike these modalities, ddMRI uses non-ionizing technology and provides advanced soft-tissue contrast, helping clinicians evaluate diagnostic questions where soft tissue characterization is essential.
One key innovation is a dental-specific field of view made possible through a dedicated dental coil and specialized software. This design focuses on dental structures, ensuring that brain tissue is not included in the scan and allowing precise imaging of teeth and surrounding anatomy. The system streamlines patient preparation and maintains an average workflow time of under 20 minutes, making it efficient for clinical use.
According to Don Tyndall,professor of Diagnostic Sciences at the University of North Carolina, MAGNETOM Free.Max Dental Edition represents a major advancement in dental imaging by providing detailed visualization of dental structures that are often difficult to capture with conventional imaging techniques, while avoiding the risks linked to ionizing radiation. The ability to analyze the same region using different ddMRI imaging sequences provides deeper insight into both hard and soft tissue pathology. This improved visualization of soft tissue structures has the potential to enhance diagnostic confidence in clinical scenarios where traditional imaging methods have limitations.
Industry Prospects Favoring the Market
Going by the data provided by Precedence Research, the magnetic resonance imaging market is valued at $8.8 billion in 2026 and expected to witness a CAGR of 3.9% through 2035.
Factors such as the increasing number of technological advancements, chronic diseases and cancer are enhancing the market expansions.
Other News
Dentsply Sirona announced expanded and renewed U.S. distribution partnerships with Benco Dental, Patterson Dental and Burkhart Dental Supply to broaden access to its dental technology ecosystem.
Under the collaborations, distributors will offer Dentsply Sirona’s full portfolio of digital technologies and consumables, enabling dental practices to adopt integrated workflows that connect scanning, design and manufacturing.
As part of the expansion, starting April 1, 2026, Burkhart Dental Supply will add Dentsply Sirona’s solutions like the CEREC system and CEREC blocks, Primescan and Primescan 2 intraoral scanners and extraoral imaging systems, including Axeos and Orthophos, to its offerings, supporting more efficient workflows and improved patient care.
XRAY’s Zacks Rank & Key Picks
Currently, XRAY has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical ISRG, Phibro Animal Health PAHC and Cardinal Health CAH.
Intuitive Surgical, sporting a Zacks Rank #1 (Strong Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rankstocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.2%.
Phibro Animal Health, currently sporting a Zacks Rank #1, reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.
PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.2% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 20.1%.
Cardinal Health, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.
CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 9.3%.
Just Released: Zacks Top 10 Stocks for 2026
Hurry – you can still get in early on our 10 top tickers for 2026. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful.
From inception in 2012 through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.
Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2026. You can still be among the first to see these just-released stocks with enormous potential.
See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Cardinal Health, Inc. (CAH): Free Stock Analysis Report
DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report
Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Comentarios
Aún no hay comentarios